CapsoVision (CV) FCF Margin (2024 - 2025)
CapsoVision (CV) posted FCF Margin of 196.17% for Q4 2025, down 22.49% sequentially from 160.15% in Q3 2025, and down 4423.0% YoY from 4.54% in Q4 2024.
CapsoVision (CV) FCF Margin (2024 - 2025) Analysis & Trends
CapsoVision has reported FCF Margin for 2 years, with the latest figure at 196.17% in Q4 2025.
- Quarterly FCF Margin fell 4423.0% year-over-year to 196.17% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 130.75% (changed N/A YoY) and the FY2025 annual result came in at 168.69%, up 220.0% from the prior year.
- FCF Margin retreated to 196.17% in Q4 2025 per CV's latest filing, from 160.15% in the prior quarter.
- Over five years, FCF Margin peaked at 151.94% in Q4 2024 and troughed at 243.16% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.90 Bn | 193.29 Bn | 7.27 Bn | 15.81% |
| 2 | Stryker | 126.09 Bn | 122.62 Bn | 4.50 Bn | 16.07% |
| 3 | Medtronic | 118.39 Bn | 109.17 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 72.77 Bn | 72.24 Bn | 3.85 Bn | 23.50% |
| 5 | Edwards Lifesciences | 52.04 Bn | 47.78 Bn | 1.35 Bn | 33.60% |
| 6 | Dexcom | 34.42 Bn | 32.47 Bn | 830.00 Mn | 14.10% |
| 7 | GE HealthCare Technologies | 33.65 Bn | 31.54 Bn | 2.18 Bn | 1.28% |
| 8 | Koninklijke Philips | 26.29 Bn | 22.97 Bn | 4.55 Bn | 5.32% |
| 9 | Steris | 23.06 Bn | 22.57 Bn | 684.20 Mn | 18.73% |
| 10 | CapsoVision | 296.38 Mn | 287.30 Mn | 1.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -196.17% |
| Sep 30, 2025 | -160.15% |
| Dec 31, 2024 | -151.94% |
| Sep 30, 2024 | -243.16% |